Hayeck TJ, Kong CY, Spechler SJ, et al. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010;23(6):451-457.
American Cancer Society. Cancer facts & figures 2021. Accessed March 8, 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf
Qumseya BJ, Bukannan A, Gendy S, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett's esophagus. Gastrointest Endosc. 2019;90(5):707-717.e1.
Thrift AP, Kramer JR, Qureshi Z, et al. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013;108(6):915-922.
Ford AC, Forman D, Reynolds PD, et al. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol. 2005;162(5):454-460.
Andrici J, Tio M, Cox MR, et al. Hiatal hernia and the risk of Barrett's esophagus. J Gastroenterol Hepatol. 2013;28(3):415-431.
Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol. 2010;105(8):1729-1738.
Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050-1061.
Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399-1412.e7.
Andrici J, Cox MR, Eslick GD. Cigarette smoking and the risk of Barrett's esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2013;28(8):1258-1273.
Thrift AP, Cook MB, Vaughan TL, et al. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014;109(10):1586-1594.
Cook MB, Coburn SB, Lam JR, et al. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut. 2018;67(3):418-529.
Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375-1383.
Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012;61(7):970-976.
Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014;79(6):897-909.e4.
Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394-398.
Fitzgerald RC, di Pietro M, Ragunath K, et al.; British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014;63(1):7-42.
Groulx S, Limburg H, Doull M, et al.; Canadian Task Force on Preventive Health Care. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease. CMAJ. 2020;192(27):E768-E777.
Shaheen NJ, Falk GW, Iyer PG, et al.; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus [published correction appears in Am J Gastroenterol. 2016; 111(7): 1077]. Am J Gastroenterol. 2016;111(1):30-50.
Ko MS, Fung KZ, Shi Y, et al. Barrett's esophagus commonly diagnosed in elderly men with limited life expectancy. J Am Geriatr Soc. 2016;64(10):e109-e111.
Rubenstein JH, McConnell D, Waljee AK, et al. Validation and comparison of tools for selecting individuals to screen for Barrett's esophagus and early neoplasia. Gastroenterology. 2020;158(8):2082-2092.
Kunzmann AT, Thrift AP, Cardwell CR, et al. Model for identifying individuals at risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2018;16(8):1229-1236.e4.
- Rubenstein JH, Raghunathan T, Doan C, et al. Validation of tools for predicting incident adenocarcinoma of the esophagus or esophagogastric junction. Am J Gastroenterol. 2021;116(5):949-957.
Ben-Menachem T, Decker GA, Early DS, et al.; ASGE Standards of Practice Committee. Adverse events of upper GI endoscopy. Gastrointest Endosc. 2012;76(4):707-718.
Rubenstein JH, Inadomi JM. Defining a clinically significant adverse impact of diagnosing Barrett's esophagus. J Clin Gastroenterol. 2006;40(2):109-115.
Codipilly DC, Chandar AK, Singh S, et al. The effect of endoscopic surveillance in patients with Barrett's esophagus: a systematic review and meta-analysis. Gastroenterology. 2018;154(8):2068-2086.e5.
Qumseya B, Sultan S, Bain P, et al.; ASGE Standards of Practice Committee. ASGE guideline on screening and surveillance of Barrett's esophagus. Gastrointest Endosc. 2019;90(3):335-359.e2.
Omidvari AH, Hazelton WD, Lauren BN, et al. The optimal age to stop endoscopic surveillance of patients with Barrett's esophagus based on sex and comorbidity: a comparative cost-effectiveness analysis. Gastroenterology. 2021;161(2):487-494.e4.
Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis. J Cancer Res Clin Oncol. 2021;147(9):2681-2691.
Jankowski JAZ, de Caestecker J, Love SB, et al.; AspECT Trial Team. Esomeprazole and aspirin in Barrett's oesophagus: a randomised factorial trial [published correction appears in Lancet. 2018; 392(10164): 2552]. Lancet. 2018;392(10145):400-408.
Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer. 2018;49(4):442-454.
Choi SE, Perzan KE, Tramontano AC, et al. Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila). 2014;7(3):341-350.
Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012;143(3):567-575.
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360(22):2277-2288.
Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett's low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112(6):849-865.
Iyer PG, Kaul V. Barrett esophagus. Mayo Clin Proc. 2019;94(9):1888-1901.
Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol. 2003;98(11):2390-2394.
Sikkema M, de Jonge PJF, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8(3):235-244.
Gatenby P, Caygill C, Wall C, et al. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. World J Gastroenterol. 2014;20(28):9611-9617.
Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut. 2003;52(8):1081-1084.
Zimmerman TG. Common questions about Barrett esophagus. Am Fam Physician. 2014;89(2):92-98.
Shalauta MD, Saad R. Barrett's esophagus. Am Fam Physician. 2004;69(9):2113-2118.